Moderna ( MRNA ) stock jumped 9% Friday after The New York Times reported new details about an effort to speed development of a cancer vaccine. Investors notably viewed the mRNA biotech company as a beneficiary.
Other pharmaceutical stocks, including Pfizer (PFE), BioNTech (BNTX), and Merck (MRK), also rose.
219.60 +22.60 (+11.47%)
At 1:11:40 p.m. EDT. Open market.
According to the New York Times, the new initiative is a public-private partnership – similar to the effort that produced COVID-19 vaccines – that involves the National Institutes of Health (NIH), the nonprofit arm of the NIH, researchers, pharmaceutical and biotechnology companies, advocacy groups, other nonprofit organizations and patients.
Stacey Adam, a senior clinical officer at the NIH Foundation, told the New York Times that she expects the program to launch in December. In 2024, the UK launched a similar program, called the Cancer Vaccine Launch Pad.
Moderna is considered a leader in mRNA-based cancer treatments. The stock rose in August thanks to positive results from a treatment against melanoma, developed with Merck.
Year to date, Moderna stock is up 627%.
This story is developing. Check back for updates.
Click here for the latest stock news and in-depth analysis, including the events that move stocks.
Read the latest financial and business news from Yahoo Finance
Gn Health
